Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inflammatory Biomarker Reduction With Fostemsavir Over 96 Weeks in Heavily Treatment-Experienced Adults With Multidrug-Resistant HIV-1 in the BRIGHTE Study

26 Aug 2024

Abstract excerpt

Background: Fostemsavir, a first-in-class attachment inhibitor that binds to the viral envelope protein gp120, is approved for heavily treatment-experienced persons with HIV-1 with limited treatment options. We explored changes in immunologic and coagulopathy parameters in the BRIGHTE study: a phase 3 trial that evaluated fostemsavir plus optimized background therapy in heavily treatment-experienced adults with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to HIV-related health complications and treatments
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39233711
DOI: 10.1093/ofid/ofae469

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inflammatory Biomarker Reduction With Fostemsavir Over 96 Weeks in Heavily Treatment-Experienced Adults With Multidrug-Resistant HIV-1 in the BRIGHTE StudyPMID 39233711Read ↗

Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.Semantic proximity Read ↗

Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1Semantic proximity Read ↗

Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation.Semantic proximity Read ↗

Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection.Semantic proximity Read ↗

Long-Term Elite Controllers of HIV-1 Infection Exhibit a Deep Perturbation of Monocyte HomeostasisSemantic proximity Read ↗

Antiviral Monocytes Increase Prior to Detectable HIV-1 Rebound ViremiaSemantic proximity Read ↗

Inflammatory Responses in HIV-1 Genetic Subtypes in Relationship with Anti-Retroviral Drug Resistance in Minna, Niger State, North Central NigeriaSemantic proximity Read ↗

Evaluating immunologic response and clinical deterioration in treatment-naive patients initiating first-line therapies infected with HIV-1 CRF01_AE and subtype B.Semantic proximity Read ↗

Summaries for patients. Treatment for resistant HIV-1 infection.Semantic proximity Read ↗

Plasma Cytokine Expression as a Marker of Immunoadjuvant Strategy in HIV-infected Patients Undergoing Early or Delayed Antiretroviral TreatmentSemantic proximity Read ↗

Non-classical monocytes predict progression of carotid artery bifurcation intima-media thickness in HIV-infected individuals on stable antiretroviral therapy.Semantic proximity Read ↗

IL-10 induces activated phenotypes of monocytes observed in virally-suppressed HIV-1-infected individuals.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.